Osteostatin-loaded bioceramics stimulate osteoblastic growth and differentiation
Source abstract
Abstract
Parathyroid hormone-related protein (PTHrP) is an important regulator of bone remodeling. Recent studies show that this protein can induce osteogenic features through its N- and C-terminal domains. Silica-based ordered mesoporous bioceramics with an SBA-15 structure - known to be bioactive and biocompatible - have recently been evaluated for their capacity to uptake and deliver L-tryptophan. This amino acid corresponds to the end position of the 107-111 domain (called osteostatin) of the native C-terminal PTHrP (107-139) fragment, whose true action in bone metabolism is still ill-defined. In the present study, we assessed some effects of the aforementioned biomaterials pressed into disks, loaded or not with osteostatin, in osteoblastic cell cultures. Our data demonstrate that both unmodified and organically modified SBA-15 loaded with this peptide increase cell growth and the expression of several osteoblastic products (alkaline phosphatase, osteocalcin, collagen, osteoprotegerin, receptor activator of nuclear factor-kappaB ligand and vascular endothelial growth factor) in osteoblastic cells. These findings support the notion that osteostatin coating confers osteogenic features to silica-based ordered mesoporous materials, which make them suitable biomaterials for bone repair.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Bone Tissue Engineering Materials · Nanoparticle-Based Drug Delivery · biodegradable polymer synthesis and properties
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (41)
Show source-provided references
1. Vallet-Regí · 2008
2. The mechanism of coupling: role for the vasculature10.1016/S8756-3282(00)80937-0 ↗
3. Parathyroid hormone-related protein: an essential physiological regulator of adult bone mass10.1210/en.2004-0509 ↗
4. Six-month daily administration of parathyroid hormone and parathyroid hormone-related protein peptides to adult ovariectomized rats markedly enhances bone mass and biomechanical properties: a comparison of human parathyroid hormone 1–34, parathyroid hormone-related protein 1–36, and SDZ-parathyroid hormone 89310.1359/jbmr.2000.15.8.1517 ↗
5. Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis10.1210/jc.2002-021122 ↗
6. Role of parathyroid hormone-related protein in the decreased osteoblast function in diabetes-related osteopenia10.1210/en.2008-1108 ↗
7. Parathyroid hormone-related protein: evidence for isoform- and tissue-specific posttranslational processing10.1021/bi00189a054 ↗
8. A carboxyl-terminal peptide from the parathyroid hormone-related protein inhibits bone resorption by osteoclasts10.1210/endo-129-4-1762 ↗
9. Tartrate resistant acid phosphatase activity in rat cultured osteoclasts is inhibited by a carboxyl terminal peptide (osteostatin) from parathyroid hormone-related protein10.1002/jcb.240540203 ↗
10. PTHrP (107–111) inhibits in vivo resorption that was stimulated by PTHrP (1–34) when applied intermittently to neonatal mice10.1007/s002239900359 ↗
11. Parathyroid hormone-related protein-(107–139) inhibits bone resorption in vivo10.1210/en.138.3.1299 ↗
12. Preserved bone mass in ovariectomized rats treated with parathyroid-hormone-related peptide (1–34) and (107–111) fragments10.1051/rnd:19940508 ↗
13. Severe growth retardation and early lethality in mice lacking the nuclear localization sequence and C-terminus of PTH-related protein10.1073/pnas.0805690105 ↗
14. Stimulation of osteoblast proliferation by C-terminal fragments of parathyroid hormone-related protein10.1359/jbmr.1999.14.6.915 ↗
15. Transient exposure to PTHrP (107–139) exerts anabolic effects through vascular endothelial growth factor receptor 2 in human osteoblastic cells in vitro10.1007/s00223-006-0099-y ↗
16. Parathyroid hormone-related protein (107–139) increases human osteoblastic cell survival by activation of vascular endothelial growth factor receptor-210.1002/jcp.21547 ↗
17. Tissue regeneration: a new property of mesoporous materials10.1016/j.solidstatesciences.2005.04.003 ↗
18. Revisiting silica based ordered mesoporous materials: medical applications10.1039/B509744D ↗
19. A mesoporous silica nanoshpere-based carrier system with chemically removable CdS nanoparticle caps for stimuli-responsive controlled release of neurotransmitters and drug molecules10.1021/ja028650l ↗
20. A new property of MCM-41: drug delivery system10.1021/cm0011559 ↗
21. Mesoporous materials for drug delivery10.1002/anie.200604488 ↗
22. Ordered mesoporous materials in the context of drug delivery systems and bone tissue engineering10.1002/chem.200600226 ↗
23. Bone-regenerative bioceramic implants with drug and protein controlled delivery capability10.1016/j.progsolidstchem.2007.10.002 ↗
24. L-Trp adsorption into silica mesoporous materials to promote bone formation10.1016/j.actbio.2007.11.009 ↗
25. Non ionic triblock and star diblock copolymer and oligomeric surfactant synthesis of highly ordered, hydrothermally stable, mesoporous silica structures10.1021/ja974025i ↗
26. Hydroxyapatite coated with hepatocyte growth factor (HGF) stimulates human osteoblasts in vitro10.1302/0301-620X.82B3.9310 ↗
27. Zambonin G, Grano M, Greco G, Oreffo ROC, Triffit JT. Hydroxyapatite coated with insulin-like growth factor 1 (IGF1) stimulates human osteoblast activity in vitro. Acta Orthop Scand 1999; 70: 217–20.10.3109/17453679909011266 ↗
28. Characterization of parathyroid hormone/parathyroid hormone-related protein receptor and signaling in hypercalcemic Walker 256 tumor cells10.1677/joe.0.1660011 ↗
29. A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein–dye-binding10.1016/0003-2697(76)90527-3 ↗
30. PH-dependent surface charging and points of zero charge. II. Update10.1016/j.jcis.2004.02.029 ↗
31. Confinement and controlled release of bisphosphonates on ordered mesoporous silica-based materials10.1021/ja062286z ↗
32. Crank · 1975
33. Modeling and comparison of dissolution profiles10.1016/S0928-0987(01)00095-1 ↗
34. A simple-model based on first-order kinetics to explain release of highly water-soluble drugs from porous dicalcium phosphate dihydrate matrices10.3109/03639049509026658 ↗
35. Functionalization degree of SBA-15 as key factor to modulate sodium alendronate dosage10.1016/j.micromeso.2008.03.025 ↗
36. An HREM study of channel structures in mesoporous silica SBA-15 and platinum wires produced in the channels10.1002/1439-7641(20010417)2:4<229::AID-CPHC229>3.0.CO;2-G ↗
37. Studies on MCM-41 mesoporous silica for drug delivery: effect of particle morphology and amine functionalisation10.1016/j.cej.2007.07.078 ↗
38. Vascular biology and bone formation: hints from HIF10.1172/JCI32518 ↗
39. Bone formation during distraction osteogenesis is dependent on both VEGFR1 and VEGFR2 signaling10.1359/jbmr.080103 ↗
40. Age-related changes in parathyroid hormone-related protein and vascular endothelial growth factor in human osteoblastic cells10.1007/s001980200120 ↗
41. Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases10.1002/1097-0142(20010801)92:3<460::AID-CNCR1344>3.0.CO;2-D ↗